{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["29(1)"],"submitter":["Gentzler RD"],"funding":["Merck &amp; Co., Inc","Merck Sharp & Dohme LLC","Celgene Inc","Merck & Co., Inc","Merck Sharp &amp; Dohme LLC"],"pubmed_abstract":["<h4>Background</h4>Combination chemotherapy and immunotherapy regimens have significantly improved survival for patients with previously untreated advanced non-small cell lung cancer (NSCLC). Improvements in overall survival (OS) in two separate pembrolizumab trials have demonstrated survival improvements over chemotherapy alone, regardless of PD-L1 status. The optimal chemotherapy backbone for combination with immunotherapy is unknown. We hypothesized nab-paclitaxel may be a well-suited platinum partner to use in combination with checkpoint inhibitor therapy for both adenocarcinoma and squamous histology and conducted a phase I/II trial to assess the efficacy of this regimen in advanced NSCLC.<h4>Methods</h4>Adult patients with previously untreated, stage IIIB/IV NSCLC (any histology) wit"],"journal":["The oncologist"],"pagination":["47-56"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10769801"],"repository":["biostudies-literature"],"pubmed_title":["Phase I/II Trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced Non-Small Cell Lung Cancer: Hoosier Cancer Research Network LUN13-175."],"pmcid":["PMC10769801"],"pubmed_authors":["Gentzler RD","Jalal SI","Hanna NH","Hall RD","Mohindra NA","Reckamp KL","Chae YK","Koczywas M","Patel JD","Helenowski IB"],"additional_accession":[]},"is_claimable":false,"name":"Phase I/II Trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced Non-Small Cell Lung Cancer: Hoosier Cancer Research Network LUN13-175.","description":"<h4>Background</h4>Combination chemotherapy and immunotherapy regimens have significantly improved survival for patients with previously untreated advanced non-small cell lung cancer (NSCLC). Improvements in overall survival (OS) in two separate pembrolizumab trials have demonstrated survival improvements over chemotherapy alone, regardless of PD-L1 status. The optimal chemotherapy backbone for combination with immunotherapy is unknown. We hypothesized nab-paclitaxel may be a well-suited platinum partner to use in combination with checkpoint inhibitor therapy for both adenocarcinoma and squamous histology and conducted a phase I/II trial to assess the efficacy of this regimen in advanced NSCLC.<h4>Methods</h4>Adult patients with previously untreated, stage IIIB/IV NSCLC (any histology) wit","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jan","modification":"2025-04-04T21:54:50.42Z","creation":"2025-02-19T05:00:43.614Z"},"accession":"S-EPMC10769801","cross_references":{"pubmed":["37390616"],"doi":["10.1093/oncolo/oyad180"]}}